Literature DB >> 27108966

A penicillin- and metronidazole-resistant Clostridium botulinum strain responsible for an infant botulism case.

C Mazuet1, E-J Yoon2, S Boyer3, S Pignier4, T Blanc5, I Doehring6, D Meziane-Cherif2, C Dumant-Forest4, J Sautereau1, C Legeay1, P Bouvet1, C Bouchier7, S Quijano-Roy8, M Pestel-Caron3, P Courvalin2, M R Popoff9.   

Abstract

The clinical course of a case of infant botulism was characterized by several relapses despite therapy with amoxicillin and metronidazole. Botulism was confirmed by identification of botulinum toxin and Clostridium botulinum in stools. A C. botulinum A2 strain resistant to penicillins and with heterogeneous resistance to metronidazole was isolated from stool samples up to 110 days after onset. Antibiotic susceptibility was tested by disc agar diffusion and MICs were determined by Etest. Whole genome sequencing allowed detection of a gene cluster composed of blaCBP for a novel penicillinase, blaI for a regulator, and blaR1 for a membrane-bound penicillin receptor in the chromosome of the C. botulinum isolate. The purified recombinant penicillinase was assayed. Resistance to β-lactams was in agreement with the kinetic parameters of the enzyme. In addition, the β-lactamase gene cluster was found in three C. botulinum genomes in databanks and in two of 62 genomes of our collection, all the strains belonging to group I C. botulinum. This is the first report of a C. botulinum isolate resistant to penicillins. This stresses the importance of antibiotic susceptibility testing for adequate therapy of botulism.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic-resistance; Botulism; Clostridium botulinum; Infant botulism; Metronidazole; Penicillin

Mesh:

Substances:

Year:  2016        PMID: 27108966     DOI: 10.1016/j.cmi.2016.04.011

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Antimicrobial Susceptibility of 260 Clostridium botulinum Type A, B, Ba, and Bf Strains and a Neurotoxigenic Clostridium baratii Type F Strain Isolated from California Infant Botulism Patients.

Authors:  Jason R Barash; Joe B Castles; Stephen S Arnon
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

2.  Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus.

Authors:  J Andrew N Alexander; Mariia Radaeva; Dustin T King; Henry F Chambers; Artem Cherkasov; Som S Chatterjee; Natalie C J Strynadka
Journal:  J Biol Chem       Date:  2020-06-09       Impact factor: 5.157

Review 3.  Human Botulism in France, 1875-2016.

Authors:  Christine Rasetti-Escargueil; Emmanuel Lemichez; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2020-05-21       Impact factor: 4.546

4.  Outbreak of Foodborne Botulism Associated with Improperly Earthenware Cheese (Koupé): A Case Report.

Authors:  Parshang Faghih Solaymani; Ardeshir Rahimzadeh; Farideh Mostafavi
Journal:  Iran J Public Health       Date:  2019-10       Impact factor: 1.429

5.  Clostridium botulinum - like organism bacteremia in a user of black tar heroin.

Authors:  Therese Battiola; Kristen Saad; Taylor Nelson; Nick Tinker; Aaron Crosby
Journal:  IDCases       Date:  2021-07-09

Review 6.  Toxemia in Human Naturally Acquired Botulism.

Authors:  Christine Rasetti-Escargueil; Emmanuel Lemichez; Michel R Popoff
Journal:  Toxins (Basel)       Date:  2020-11-13       Impact factor: 4.546

Review 7.  Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review.

Authors:  Robertino Dilena; Mattia Pozzato; Lucia Baselli; Giovanna Chidini; Sergio Barbieri; Concetta Scalfaro; Guido Finazzi; Davide Lonati; Carlo Alessandro Locatelli; Alberto Cappellari; Fabrizio Anniballi
Journal:  Toxins (Basel)       Date:  2021-12-02       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.